摘要
目的探讨地塞米松联合硼替佐米治疗多发性骨髓瘤对肾功能和炎症因子的影响。方法选取2021年6月至2022年6月抚州市第一人民医院收治的80例多发性骨髓瘤患者作为研究对象,按照随机数字表法分为对照组与观察组,每组40例。对照组给予传统化疗治疗,观察组给予地塞米松联合硼替佐米治疗。比较两组临床疗效、治疗前后肾功能指标[血清β_(2)-微球蛋白(β_(2)-MG)、血肌酐(SCr)、尿素氮(BUN)]、血清炎症因子[C反应蛋白(CRP)、白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、白细胞介素-17(IL-17)]水平及不良反应发生情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组β_(2)-MG、SCr、BUN水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组CRP、IL-6、IL-17水平均低于治疗前,IL-2水平均高于治疗前,且观察组CRP、IL-6、IL-2、IL-17低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论采取地塞米松联合硼替佐米治疗多发性骨髓瘤疗效显著,能有效降低患者机体的炎症水平,改善患者肾功能,且不良反应较少,值得临床推广应用。
Objective To explore the effect of dexamethasone combined with bortezomib in the treatment of multiple myeloma on renal function and inflammatory factors.Methods 80 patients with multiple myeloma admitted to Fuzhou First People's Hospital from June 2021 to June 2022 were selected as the research subjects,and they were divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The control group were treated with traditional chemotherapy,while the observation group were treated with dexamethasone combined with bortezomib,the clinical efficacy and renal function indexes(serumβ_(2)-microglobulin[β_(2)-MG],serum creatinine[SCr],blood urea nitrogen[BUN]),serum inflammatory factors(C-reactive protein[CRP],interleukin-2[IL-2],interleukin-6[IL-6],interleukin-17[IL-17])levels before and after treatment and adverse reactions were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels ofβ_(2)-MG,SCr and BUN of the two groups were lower than before treatment,and the observation group was lower than the control group,the differences were statis-tically significant(P<0.05).After treatment,the levels of CRP,IL-6 and IL-17 of the two groups were lower than before treatment,and the levels of IL-2 were higher than before treatment,and the levels of CRP,IL-6,IL-2 and IL-17 in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The treatment of multiple myeloma with dexamethasone combined with bortezomib can effectively reduce the inflammatory levels of the patients,help improve the renal function of the patient,and has few adverse reactions,which is worthy of clinical promotion and application.
作者
龚菊萍
吴仲林
王淑芳
GONG Juping;WU Zhonglin;WANG Shufang(Department of Hematology,Fuzhou First People's Hospital,Fuzhou,Jiangxi,344000,China)
出处
《当代医学》
2024年第7期81-85,共5页
Contemporary Medicine
关键词
地塞米松
硼替佐米
多发性骨髓瘤
肾功能
炎症因子
不良反应
Dexamethasone
Bortezomib
Multiple myeloma
Renal function
Inflammatory factors
Adverse reactions
